ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company pioneering therapies that harness the body’s immune system to combat cancer, with a mission to revolutionize cancer care.

Early exposure to research ethics education can have a lasting impact on students’ professional behavior and decision-making, fostering a culture of ethical awareness and responsibility.

ALX Oncology Holdings Inc. faces financial challenges and a declining stock price, but remains committed to advancing its immuno-oncology therapies and potentially delivering breakthrough cancer treatments.